50 likes | 281 Views
Resolute all comers trial. Objective: To compare the efficacy and safety of the new generation ZES stent versus the everolimus eluting stent. Study: Multicenter, single blind, randomized non- inferiority trial.
E N D
Resolute all comers trial Objective: To compare the efficacy and safety of the new generation ZES stent versus the everolimus eluting stent. Study: Multicenter, single blind, randomized non- inferiority trial. Population: Patients with stable CAD and ACS (NSTEMI, STEMI, UA). Size 2.25-4 mm. No restrictions on no of stents, no of treated lesions, lesion length, treated vessel Endpoint: TLF: cardiac death, MI, clinically driven TLR at 1 year f-up.
Resolute all comers trial Zotarolimus DES (Endeavor- Resolute) N=1140 Planned f-up angio 13 m. 20% of patients Patients enrolled N=2292 Everolimus DES (Xience V) N=1152 Planned f-up angio 13 m. 20% of patients
Resolute all comers trial Event rate at 1 year f-up (%) p=0.94 p=0.08 p=0.92 p=0.50 p=0.01
Resolute all comers trial QCA at 13 monthsf-upangio Late loss (mm)
Resolute all comers trial Conclusion: At follow-up the new generation ZES (Endeavor-Resolute) was foundto be non- inferior to the everolimus eluting Xience V stent in a population of patients with minimal exclusion criteria. Serruys et al. N Engl J Med 2010;363:136-46